Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Today 06:08
BRIEF-UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth Oct 22 (Reuters) - Ucb SA UCB.BR:
STRONG PERFORMANCE DRIVES FURTHER UPGRADE TO UCB'S 2026 FINANCIAL GUIDANCE
ADJUSTED EBITDA GROWTH EXPECTED IN LOW- TO MID-FORTIES AT CONSTANT EXCHANGE RATES, UP FROM MID-TEENS TO LOW-TWENTIES
HIGHER REVENUE GROWTH IS DRIVING SIGNIFICANT OPERATING LEVERAGE
UPGRADE IS DRIVEN BY BIMZELX STRONGER PERFORMANCE IN U.S
CIMZIA SOLID CONTRIBUTION REFLECTING CONTINUED VOLUME GROWTH AND MORE FAVORABLE PRICING
Source text: ID:nPLXV1GQCL
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsUCB tops STOXX after guidance upgrade on better drug sales
UCB upgrades 2026 guidance on strong US Bimzelx sales (updated)
UCB upgrades 2026 guidance on strong US Bimzelx sales
Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis